FDA Role in Drug Shortages.
- Published in:
- JAMA: Journal of the American Medical Association, 2012, v. 308, n. 6, p. 558, doi. 10.1001/jama.2012.8914
- By:
- Publication type:
- Article
Works matching United States House Committee on Oversight and Government Reform
Results: 18
1
2
FDA Preemption.
- Published in:
- JAMA: Journal of the American Medical Association, 2008, v. 300, n. 22, p. 2599, doi. 10.1001/jama.2008.751
- By:
- Publication type:
- Article
3
Surge Capacity.
- Published in:
- JAMA: Journal of the American Medical Association, 2008, v. 299, n. 22, p. 2620, doi. 10.1001/jama.299.22.2620-b
- By:
- Publication type:
- Article
4
The United States and Pakistan Relations and Cooperation: Key to Regional Stability.
- Published in:
- 2007
- By:
- Publication type:
- Excerpt
5
Policy Watch. Drug recalls, shortages suggest FDA needs greater authority for manufacturer compliance.
- Published in:
- Formulary, 2010, v. 45, n. 8, p. 265
- By:
- Publication type:
- Article
6
The legend of Saint Alan: Larnaudie and Stiegler in the Oversight Committee Room.
- Published in:
- French Cultural Studies, 2020, v. 31, n. 3, p. 173, doi. 10.1177/0957155819874750
- By:
- Publication type:
- Article
7
Outsourcing Questioned.
- Published in:
- JAMA: Journal of the American Medical Association, 2011, v. 305, n. 6, p. 553, doi. 10.1001/jama.2011.97
- By:
- Publication type:
- Article
8
Mylan and the EpiPen: Increased Access or Price Gouging?
- Published in:
- Business Case Journal, 2017, v. 24, n. 2, p. 1
- By:
- Publication type:
- Article
9
Statements to the congress.
- Published in:
- Federal Reserve Bulletin, 1999, v. 85, n. 4, p. 252
- Publication type:
- Article
10
A critical institution for parliamentary oversight.
- Published in:
- Parliamentarian, 2007, v. 88, n. 2, p. 131
- By:
- Publication type:
- Article
11
Incentives for New Antibiotics.
- Published in:
- JAMA: Journal of the American Medical Association, 2012, v. 308, n. 6, p. 558, doi. 10.1001/jama.2012.9558
- By:
- Publication type:
- Article
12
Improving Statutory Deadlines on Agency Action: Learning from the SEC's Missed Deadlines Under the JOBS Act.
- Published in:
- Texas Law Review, 2014, v. 92, n. 4, p. 995
- By:
- Publication type:
- Article
13
Redundant Drug Benefits.
- Published in:
- JAMA: Journal of the American Medical Association, 2008, v. 300, n. 2, p. 160, doi. 10.1001/jama.300.2.160-d
- By:
- Publication type:
- Article
14
Lead Paint Rule Criticized.
- Published in:
- JAMA: Journal of the American Medical Association, 2008, v. 299, n. 18, p. 2141, doi. 10.1001/jama.299.18.2141-c
- By:
- Publication type:
- Article
15
Subpoenas Refused.
- Published in:
- JAMA: Journal of the American Medical Association, 2008, v. 299, n. 10, p. 1124, doi. 10.1001/jama.299.10.1124-c
- By:
- Publication type:
- Article
16
Plant Inspections Lag.
- Published in:
- JAMA: Journal of the American Medical Association, 2008, v. 299, n. 10, p. 1124, doi. 10.1001/jama.299.10.1124-a
- By:
- Publication type:
- Article
17
Regulating the Regulators: The Conflict between the Congressional Oversight Subcommittee and the FCC.
- Published in:
- Journal of Broadcasting & Electronic Media, 2010, v. 54, n. 2, p. 194, doi. 10.1080/08838151003737949
- By:
- Publication type:
- Article
18
SAFE AND AFFORDABLE BIOTECH DRUGS: THE NEED FOR A GENERIC PATHWAY.
- Published in:
- Journal of Current Issues in Crime, Law & Law Enforcement, 2009, v. 2, n. 2/3, p. 271
- Publication type:
- Article